TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 686527

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 55
Study: 31359813

Group type: EXPERIMENTAL
Intervention: Needle-free injector (NFI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Glargine pen (GP)
Number of subjects: 62
Study: 28131974

Group type: EXPERIMENTAL
Intervention: 3TG (three 60min sessions/week)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 2TG (two 60min sessions/week)
Number of subjects: 58
Study: 25911987

Group type: EXPERIMENTAL
Intervention: narafilcon A
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: delefilcon A
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: filcon II 3
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All brands
Number of subjects: 39
Study: 23571304

Group type: EXPERIMENTAL
Intervention: directive counseling and sound therapy using conventional sound generators
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: directive counseling and placebo sound generators
Number of subjects: 228

Group type: COMPARATOR
Intervention: standard of care as administered in the military
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: conventional sound generators
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: placebo sound generators
Number of subjects: 228
Study: 21393623

Group type: EXPERIMENTAL
Intervention: HIV prevention program
Number of subjects: 246

Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 246
Study: 19528519

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 756

Group type: COMPARATOR
Intervention: Combined vitamin E and placebo groups
Number of subjects: 756

Group type: COMPARATOR
Intervention: Nondepressed participants
Number of subjects: 756
Study: 17159758

Group type: EXPERIMENTAL
Intervention: 15 mL/kg of hydroxyethyl starch 6% (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 40
Study: 15571637

Group type: EXPERIMENTAL
Intervention: comicronized fenofibrate 200 mg daily
Number of subjects: 9795

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 9795
Study: 11213597

Group type: EXPERIMENTAL
Intervention: Acarbose (52 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (48 patients)
Number of subjects: 100
Study: 9763251

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine and smoking cessation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonsmoking controls
Number of subjects: 10
Study: 29276018

Group type: EXPERIMENTAL
Intervention: Health Action Process Approach
Number of subjects: 1933
Study: 28851399

Group type: EXPERIMENTAL
Intervention: Simple dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue-glue as a dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 0
Study: 26096013

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation during airway clearance treatments
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comprehensive inpatient care (control group)
Number of subjects: 40
Study: 23477676

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4752

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4752
Study: 19519911

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Manipulation followed by exercise
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Best care in general practice
Number of subjects: 1334
Study: 17720102

Group type: COMPARATOR
Intervention: Control group (n=27) received dietary advice to match intake with 1.2 g of protein per kg of ideal body weight and 25 cal/kg ideal body weight.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intervention group (n=28) received dietary advice to match energy intake with estimated total energy expenditure, with a protein intake of 0.8 to 1.0 g/kg.
Number of subjects: 59
Study: 14728998

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (androgens)
Number of subjects: 0
Study: 11142664

Group type: EXPERIMENTAL
Intervention: Elastase activity measured in gingival crevicular fluid (GCF)
Number of subjects: 12
Study: 9833603

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 30 g L-arginine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 6 g L-arginine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral ingestion of 6 g L-arginine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (for comparison)
Number of subjects: 8
Study: 7867963

Group type: EXPERIMENTAL
Intervention: Cognitive impairment, particularly impaired orientation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Evidence of previous cerebrovascular accident
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Incoordination as measured clinically
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Inability to perform the 'Get‐up‐and‐go' test
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Use of psycho‐active medications
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Impaired orientation, psycho‐active drug use, evidence of stroke, and impaired performance in the 'Get‐up‐and‐go' test
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Number of identified risk factors
Number of subjects: 88
Study: 2774232

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia plus light general anesthesia (group TEA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: General anesthesia with halothane (group H)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (group NLA)
Number of subjects: 105
Study: 561495

Group type: EXPERIMENTAL
Intervention: Dexamethasone (12 mg per day orally for three successive days)
Number of subjects: 0
Study: 31433573

Group type: EXPERIMENTAL
Intervention: 4-odorant training (PEA, lemon, eucalyptus, clove oils)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PEA training (1 bottle of PEA)
Number of subjects: 90
Study: 24863414

Group type: EXPERIMENTAL
Intervention: Oral antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; alpha‐lipoic acid, 600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23800565

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg for 7 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21716269

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 200
Study: 18769961

Group type: EXPERIMENTAL
Intervention: 100 microg/day of transdermal 17beta‐estradiol for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 34
Study: 17934931

Group type: EXPERIMENTAL
Intervention: promestriene 10 mg daily, by vaginal capsule, for 21 days before the operation
Number of subjects: 98

Group type: COMPARATOR
Intervention: TVT (Tension‐free Vaginal Tape) surgical procedure without pharmacological preparation
Number of subjects: 98
Study: 15246941

Group type: EXPERIMENTAL
Intervention: Short contact dithranol
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: UVB-phototherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Inpatient dithranol treatment
Number of subjects: 250
Study: 11482615

Group type: EXPERIMENTAL
Intervention: Active counterpositioning
Number of subjects: 74

Group type: COMPARATOR
Intervention: Orthotic helmets
Number of subjects: 74
Study: 9611022

Group type: EXPERIMENTAL
Intervention: Intramedullary hip-screw
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compression hip-screw with plate
Number of subjects: 100
Study: 7825753

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ZCG) during exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ZCG) during upright exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: SVZCG compared with SVCO2
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pulse-O2 as an index to SV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ZCG parameters dZ/dtmax and LVET
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SVZCG calculated with the Kubicek equation
Number of subjects: 7
Study: 3071615

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTRX) 10 mg/kg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTRX) 20 mg/kg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CTRX)
Number of subjects: 168
Study: 29388802

Group type: EXPERIMENTAL
Intervention: Graphic health warnings (GHWs) evoked negative emotions high in arousal activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive reactions to GHWs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived health risks of smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHW-evoked negative emotions
Number of subjects: 0
Study: 27754998

Group type: EXPERIMENTAL
Intervention: High-Velocity Resistance Training (HV)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-Velocity Resistance Training (LV)
Number of subjects: 46
Study: 25804431

Group type: EXPERIMENTAL
Intervention: Perk Tutor (3D display with conventional ultrasound imaging)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (conventional ultrasound only)
Number of subjects: 24
Study: 24105750

Group type: EXPERIMENTAL
Intervention: Interferon α-2b, 3 MU three times weekly for 18 months
Number of subjects: 221

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 221
Study: 21867991

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 27
Study: 19264721

Group type: EXPERIMENTAL
Intervention: EHF‐LGG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHF‐LGG
Number of subjects: 0

Group type: COMPARATOR
Intervention: EHF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHF and PHF‐LGG
Number of subjects: 0
Study: 17364603

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Applied Relaxation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Transdermal Estrogens
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral Estrogens
Number of subjects: 102

Group type: COMPARATOR
Intervention: Transdermal Placebo
Number of subjects: 102
Study: 15465845

Group type: EXPERIMENTAL
Intervention: Leucocyte depleting arterial line filter
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard 40-mm arterial line filter
Number of subjects: 32
Study: 11887429

Group type: EXPERIMENTAL
Intervention: Margarine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 77
Study: 9840216

Group type: EXPERIMENTAL
Intervention: Experimental sustained release tablet containing dextromethorphan hydrobromide (DXP‐HBr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Marketed sustained release DXP‐HBr suspension
Number of subjects: 6
Study: 8040016

Group type: EXPERIMENTAL
Intervention: Neurosurgery plus radiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 66
Study: 2690314

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 786677

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg sublingually
Number of subjects: 10
Study: 31397261

Group type: EXPERIMENTAL
Intervention: Teen Mental Health First Aid (MHFA) training
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: eLearning MHFA
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Blended eLearning MHFA
Number of subjects: 2251

Group type: COMPARATOR
Intervention: Physical first aid training
Number of subjects: 2251

Group type: COMPARATOR
Intervention: eLearning physical first aid
Number of subjects: 2251
Study: 30084233

Group type: EXPERIMENTAL
Intervention: 0.0625 mg linaclotide
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 0.125 mg linaclotide
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 0.25 mg linaclotide
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 0.5 mg linaclotide
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 26086326

Group type: EXPERIMENTAL
Intervention: Interval training (IT) program at 70-110% of workload reached at the ventilatory anaerobic threshold (VAT) for 16 weeks, 30-40 minutes each session, 3 times a week.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Interval training (IT) program for noCAD group.
Number of subjects: 64
Study: 24810970

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22341925

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent
Number of subjects: 6069

Group type: COMPARATOR
Intervention: CYPHER sirolimus-eluting stent
Number of subjects: 6069

Group type: COMPARATOR
Intervention: TAXUS stent
Number of subjects: 6069
Study: 20357077

Group type: EXPERIMENTAL
Intervention: 1 serving/d of pistachios (1 PD; 10% energy from pistachios; 30% total fat)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 servings/d of pistachios (2 PD; 20% energy from pistachios; 34% total fat)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 servings/d of pistachios (2 PD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 serving/d of pistachios (1 PD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lower‐fat control diet without pistachios (25% total fat)
Number of subjects: 28
Study: 17620510

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMCs)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15668818

Group type: EXPERIMENTAL
Intervention: Risperidone (1 to 4 mg/day, mean dosage 1.45±0.08 mg/day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Risperidone (open-label treatment after 4 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (initial treatment for 4 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo switched to open-label risperidone
Number of subjects: 77
Study: 11876001

Group type: EXPERIMENTAL
Intervention: Antibacterial therapy (ABT) in 30-34 week neonates
Number of subjects: 65

Group type: COMPARATOR
Intervention: No antibacterial therapy (ABT) in 30-34 week neonates
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Antibacterial therapy (ABT) in neonates < 30 weeks
Number of subjects: 65
Study: 10098560

Group type: EXPERIMENTAL
Intervention: Adult and Child Surveys
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only Child Survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Adult and Child Surveys
Number of subjects: 0
Study: 7586114

Group type: COMPARATOR
Intervention: Placebo (0/0)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg at 21:00 and placebo at 06:30 (150/0)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg at 21:00 and 06:30 (150/150)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at 21:00 and placebo at 06:30 (300/0)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Placebo at 21:00 and nizatidine 300 mg at 06:30 (0/300)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at 21:00 and 06:30 (300/300)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (0/0)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 0/150, 150/150, 0/300, and 300/300 groups
Number of subjects: 175
Study: 1703655

Group type: EXPERIMENTAL
Intervention: Micronised form of Phenytoinum "Polfa"
Number of subjects: 15

Group type: COMPARATOR
Intervention: Foreign drug
Number of subjects: 15
Study: 7410574

Group type: EXPERIMENTAL
Intervention: Therapist with 80% similar attitudes
Number of subjects: 128

Group type: COMPARATOR
Intervention: Therapist with 20% similar attitudes
Number of subjects: 128
Study: 29226799

Group type: EXPERIMENTAL
Intervention: School-based cognitive-behavioral depression prevention program (DISA), presented once per week for 10 weeks.
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was).
Number of subjects: 462
Study: 28131530

Group type: EXPERIMENTAL
Intervention: Vancomycin dosing algorithm based on estimated glomerular filtration rate from cystatin C levels (eGFRcr‐cys)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Vancomycin dosing algorithm based on estimated creatinine clearance (eCLcr) using the Cockcroft‐Gault formula
Number of subjects: 399
Study: 25832738

Group type: EXPERIMENTAL
Intervention: 4-point scale (forced choice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-point scale with a 'neither' mid-point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-point scale with 'no opinion' option
Number of subjects: 0
Study: 24169062

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms once daily
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 21454393

Group type: EXPERIMENTAL
Intervention: APD-A
Number of subjects: 25

Group type: COMPARATOR
Intervention: APD-C
Number of subjects: 25
Study: 19570573

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (200 microg, subcutaneously, three times per week)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo (equivalent to interferon gamma-1b)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 17344505

Group type: EXPERIMENTAL
Intervention: Viable probiotics
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Probiotic sonicates
Number of subjects: 28
Study: 15061268

Group type: EXPERIMENTAL
Intervention: Automated LVEF calculation using GBPS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Manual LVEF calculation using GBPS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of manual and automated GBPS LVEF calculations
Number of subjects: 22
Study: 11594897

Group type: EXPERIMENTAL
Intervention: Office-based methadone maintenance from primary care physicians (n = 22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care at an NTP (n = 24)
Number of subjects: 47
Study: 9767357

Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids (4.8 g daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Antioxidants (150 mg of vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8311284

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.015, 0.03, 0.045, or 0.06 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.125, 0.25, 0.75, or 1 mg/kg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 56

Group type: COMPARATOR
Intervention: Neostigmine vs Edrophonium
Number of subjects: 56
Study: 3613578

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo-control
Number of subjects: 9
Study: 31595608

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 58.8 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29927865

Group type: EXPERIMENTAL
Intervention: Health worker training on the 'Ten Steps for Healthy Feeding for Children from Birth to Two Years of age' (n = 206)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (n = 181)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Health worker training (intervention)
Number of subjects: 387
Study: 27055417

Group type: EXPERIMENTAL
Intervention: Once-daily colchicine dosage
Number of subjects: 92

Group type: COMPARATOR
Intervention: Twice-daily colchicine dosage
Number of subjects: 92
Study: 26683473

Group type: EXPERIMENTAL
Intervention: 12 month, individually tailored weight maintenance intervention
Number of subjects: 0
Study: 23608920

Group type: EXPERIMENTAL
Intervention: Dabrafenib administered in nonmicronized form (larger particle size) under fasting conditions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dabrafenib administered in HPMC capsules
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dabrafenib administered in gelatin capsules
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dabrafenib administered under fasting conditions
Number of subjects: 28
Study: 15920417

Group type: EXPERIMENTAL
Intervention: Crystalloid resuscitation (Parkland formula)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Plasma resuscitation
Number of subjects: 31
Study: 12183009

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 17
Study: 10521168

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 8808216

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.125 microgram/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1961961

Group type: EXPERIMENTAL
Intervention: Room-temperature (17-24 degrees C) thermodilution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold (5 degrees C) thermodilution
Number of subjects: 20
Study: 6789008

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) at 35 calories/kgm/day for at least 14 days postoperatively.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Customary enteral alimentation by feeding tubes (Control).
Number of subjects: 69
Study: 31441801

Group type: EXPERIMENTAL
Intervention: Cardiac electrophysiological procedures without analgosedation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low-dose midazolam
Number of subjects: 101

Group type: COMPARATOR
Intervention: Patient-staff interaction mode
Number of subjects: 101

Group type: COMPARATOR
Intervention: Psychosocial factors (depressive, anxiety, somatic symptom scales)
Number of subjects: 101